BRPI1011098A2 - fases cristalinas de (2-piridin-3-il-etil)-amida de ácido 2'-{[2-(4-metóxi-fenil)-acetilamino]metil}-bifenil-2-carboxílico. - Google Patents
fases cristalinas de (2-piridin-3-il-etil)-amida de ácido 2'-{[2-(4-metóxi-fenil)-acetilamino]metil}-bifenil-2-carboxílico.Info
- Publication number
- BRPI1011098A2 BRPI1011098A2 BRPI1011098A BRPI1011098A BRPI1011098A2 BR PI1011098 A2 BRPI1011098 A2 BR PI1011098A2 BR PI1011098 A BRPI1011098 A BR PI1011098A BR PI1011098 A BRPI1011098 A BR PI1011098A BR PI1011098 A2 BRPI1011098 A2 BR PI1011098A2
- Authority
- BR
- Brazil
- Prior art keywords
- acetylamino
- pyridin
- biphenyl
- methoxy
- phenyl
- Prior art date
Links
- CHDSRMIDIQABTP-UHFFFAOYSA-N 2-[2-[[[2-(4-methoxyphenyl)acetyl]amino]methyl]phenyl]-n-(2-pyridin-3-ylethyl)benzamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCC1=CC=CC=C1C1=CC=CC=C1C(=O)NCCC1=CC=CN=C1 CHDSRMIDIQABTP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09007330 | 2009-06-03 | ||
| US30622210P | 2010-02-19 | 2010-02-19 | |
| PCT/EP2010/057273 WO2010139585A2 (en) | 2009-06-03 | 2010-05-26 | Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011098A2 true BRPI1011098A2 (pt) | 2016-04-12 |
Family
ID=41171057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011098A BRPI1011098A2 (pt) | 2009-06-03 | 2010-05-26 | fases cristalinas de (2-piridin-3-il-etil)-amida de ácido 2'-{[2-(4-metóxi-fenil)-acetilamino]metil}-bifenil-2-carboxílico. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9056833B2 (pt) |
| EP (1) | EP2438045B1 (pt) |
| JP (1) | JP5698226B2 (pt) |
| KR (1) | KR20120016265A (pt) |
| CN (1) | CN102459181B (pt) |
| AU (1) | AU2010255847B2 (pt) |
| BR (1) | BRPI1011098A2 (pt) |
| CA (1) | CA2763962A1 (pt) |
| IL (1) | IL216661A0 (pt) |
| MX (1) | MX2011010427A (pt) |
| RU (1) | RU2011151399A (pt) |
| SG (1) | SG175703A1 (pt) |
| WO (1) | WO2010139585A2 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20115115A0 (fi) | 2011-02-04 | 2011-02-04 | Oulun Yliopisto | Menetelmä disulfidisidoksia sisältävien proteiinien tuottamiseksi prokaryoottisytoplasmassa |
| WO2025068591A1 (en) | 2023-09-28 | 2025-04-03 | Mosanna Therapeutics Ag | Intranasal formulations for treating obstructive sleep apnea |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9307527D0 (en) * | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| US6531495B1 (en) | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| DE102004009931A1 (de) * | 2004-02-26 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
| RU2436577C2 (ru) | 2006-04-27 | 2011-12-20 | Санофи-Авентис Дойчланд Гмбх | Ингибиторы ионных task-1 и task-3 каналов |
-
2010
- 2010-05-26 US US13/375,363 patent/US9056833B2/en active Active
- 2010-05-26 KR KR1020117028892A patent/KR20120016265A/ko not_active Withdrawn
- 2010-05-26 WO PCT/EP2010/057273 patent/WO2010139585A2/en not_active Ceased
- 2010-05-26 EP EP10724026.9A patent/EP2438045B1/en active Active
- 2010-05-26 AU AU2010255847A patent/AU2010255847B2/en not_active Ceased
- 2010-05-26 CA CA2763962A patent/CA2763962A1/en not_active Abandoned
- 2010-05-26 MX MX2011010427A patent/MX2011010427A/es not_active Application Discontinuation
- 2010-05-26 BR BRPI1011098A patent/BRPI1011098A2/pt not_active IP Right Cessation
- 2010-05-26 RU RU2011151399/04A patent/RU2011151399A/ru not_active Application Discontinuation
- 2010-05-26 JP JP2012513545A patent/JP5698226B2/ja not_active Expired - Fee Related
- 2010-05-26 SG SG2011070695A patent/SG175703A1/en unknown
- 2010-05-26 CN CN201080032542.7A patent/CN102459181B/zh not_active Expired - Fee Related
-
2011
- 2011-11-28 IL IL216661A patent/IL216661A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2438045A2 (en) | 2012-04-11 |
| RU2011151399A (ru) | 2013-07-20 |
| JP2012528816A (ja) | 2012-11-15 |
| MX2011010427A (es) | 2011-10-17 |
| EP2438045B1 (en) | 2016-10-05 |
| KR20120016265A (ko) | 2012-02-23 |
| WO2010139585A2 (en) | 2010-12-09 |
| JP5698226B2 (ja) | 2015-04-08 |
| AU2010255847B2 (en) | 2015-04-30 |
| CN102459181A (zh) | 2012-05-16 |
| CN102459181B (zh) | 2014-05-07 |
| US9056833B2 (en) | 2015-06-16 |
| WO2010139585A3 (en) | 2011-05-05 |
| AU2010255847A1 (en) | 2011-12-22 |
| SG175703A1 (en) | 2011-12-29 |
| CA2763962A1 (en) | 2010-12-09 |
| IL216661A0 (en) | 2012-02-29 |
| US20120071520A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1053I1 (fr) | Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1 | |
| BRPI1012004A2 (pt) | "forma farmacêutica" | |
| BR112012004593A2 (pt) | "método" | |
| BR112012010595A2 (pt) | "dispensdor" | |
| DK2029524T3 (da) | Fremgangsmåde til fremstilling af 2-[4-(3- og 2-fluorbenzyloxy)benzyl-amino]propanamider | |
| EP2488283A4 (en) | ADDITIVE FOR UREA SOLUTIONS | |
| HRP20150878T1 (xx) | Kondenzirani heteroaromatski pirolidinoni kao inhibitori syk | |
| BRPI1009235A (pt) | acetamidas substítuidas por 2-(hetero)arila, n-(hetero)arila e seus usos, e composição farmacêutica | |
| ATE517097T1 (de) | Thiazol- und oxazolsubstituierte arylamide | |
| EP2298750A4 (en) | NOVEL ISOXAZOLE DERIVATIVE | |
| IL220111B (en) | 2-pyridone compounds | |
| BR112012003701A2 (pt) | "novos antagonistas de quinolina-hepcidina" | |
| BRPI0924746A2 (pt) | "elemento delizante" | |
| EP2524060A4 (en) | ASSAY FOR JC VIRUS ANTIBODIES | |
| ZA201003909B (en) | Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide | |
| EP2656872A4 (en) | ELECTRODE PAD FOR IONTOPHORESIS | |
| EP2431620A4 (en) | OSZILLATIONSVERBINDER | |
| BRPI1007934A2 (pt) | "dabigatrana liofilizada" | |
| BRPI1011931A2 (pt) | trans-4[[(5s)-5-[[[3,5-bis(trifluorometil)fenil]metil] de ácido(2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetra-hidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclo-hexanocarboxílico | |
| EP2602209A4 (en) | Actuator for aerosol container | |
| BRPI0922645A2 (pt) | "arilamidas tiadiazol substituídas". | |
| PL2124946T3 (pl) | Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji | |
| BRPI1011822A2 (pt) | "compostos de 3-substituída-8-substituída-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-ona e sua aplicação" | |
| BRPI0817136A2 (pt) | "aba de fixação" | |
| EP1976844A4 (en) | IMPROVED METHOD FOR PURE DULOXETIN HYDROCHLORIDE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/306,222 DE 19/02/2010, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |